Chronic inflammatory demyelinating polyradiculoneuropathy: Revisiting the role of intravenous immmunoglobulins

Israel Medical Association Journal

Volumn 15, Issue 6, 2013, Pages 293-294

  Chapman, Joab ^a   Shoenfeld, Yehuda ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Autoantibodies; Autoimmunity; Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP); Guillain Barre acute; Intravenous immunoglobulin (IVIg); Peripheral neuropathy; Syndrome (GBS)

Indexed keywords

FC RECEPTOR IIA; GAMMA INTERFERON; IMMUNOGLOBULIN; INTERLEUKIN 2; PREDNISONE;

AREFLEXIA; EDITORIAL; GUILLAIN BARRE SYNDROME; HUMAN; LOADING DRUG DOSE; MOTOR NEUROPATHY; PHARMACOGENOMICS; PLASMAPHERESIS; POLYRADICULONEUROPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNSPECIFIED SIDE EFFECT; WEAKNESS;

AUTOIMMUNITY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84879528721     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (19)

1. Peltier AC, Donofrio PD. Chronic inflammatory demyelinating polyradiculoneuropathy: from bench to bedside. Semin Neurol 2012; 32: 187-95.
2. Jacob S, Rajabally YA. Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies http://www.ncbi.nlm.nih.gov/pubmed/?term=Jacob%20S%5Bauth%5D. Curr Neuropharmacol 2009; 7: 337-42.
3. Kondo N, Kasahara K, Kameyama T, et al. Intravenous immunoglobulins suppress immunoglobulin productions by suppressing Ca(2+)- dependent signal transduction through Fc gamma receptors in B lymphocytes. Scand J Immunol 1994; 40: 37-42.
4. Stohl W, Elliot JE. In vitro inhibition by intravenous immunoglobulin of human T celldependent B cell differentiation induced by staphylococcal superantigens. Clin Immunol Immunopathol 1996; 79: 122-33.
5. Blank M, Shoenfeld Y. Sialic acid-IVIg targeting CD, 22. Blood 2010; 116: 1630-2.
6. Kessel A, Peri R, Haj T, et al. IVIG attenuates TLR- 9 activation in B cells from SLE patients. J Clin Immunol 2011; 31: 31-8.
7. Mimouni D, Blank M, Payne AS, et al. Efficacy of intravenous immunoglobulin (IVIG) affinitypurified anti-desmoglein anti-idiotypic antibodies in the treatment of an experimental model of pemphigus vulgari. Clin Exp Immunol 2010; 162: 543-9.
8. Djoumerska-Alexieva I, Pashova S, Vassilev T, Pashov A. The protective effect of modified intravenous immunoglobulin in LPS sepsis model is associated with an increased IRA B cells response. Autoimmun Rev 2013; 12 (6): 653-6.
9. Cousens LP, Tassone R, Mazer BD, Ramachandiran V, Scott DW, De Groot AS. Tregitope update: mechanism of action parallels IVIg. Autoimmun Rev 2013; 12 (3): 436-43.
10. Lutz HU, Stammler P, Jelezarova E, Nater M, Spath PJ. High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes. Blood 1996; 88:184-93.
11. Dalakas MC. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile [Review]. Pharmacol Ther 2004; 102: 177-93.
12. Zhang G, Lopez HH. Anti-ganglioside antibodymediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies. Brain 2004; 127: 1085-100.
13. Hahn AF, Bolton CE, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, cross-over study. Brain 1996; 119: 1067-77.
14. Mendell JR, Barohn RJ. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001; 56: 445-9.
15. Dyck PJ, O'brien PC, Oviatt KF, et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982; 11: 136-41.
16. Hughes RA, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate-chromatrography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomized placebo-controlled trial. Lancet Neurol 2008; 7: 136-44.
17. Donofrio PD, Bril V, Dalakas MC, et al. Safety and tolerability of immune globulin intravenous in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol 2010; 67: 1082-8.
18. Iijima M, Tomita M, Morozumi S, et al. Single nucleotide polymorphism of TAG-1 influences IVIg responsiveness of Japanese patients with CIDP. Neurology 2009; 73: 1348-52.
19. Seguro LP, Rosario C, Shoenfeld Y. Long-term complications of past glucocorticoid use. Autoimmun Rev 2013, 12 (5): 629-32